Medidata hit by $4.8m wire fraud, but says customer clinical trial data is safe

By Gareth Macdonald contact

- Last updated on GMT

Medidata hit by $4.8m wire fraud, but says customer data is safe

Related tags: Clinical trial data, Contract research organization, Clinical trial

Fraudsters who hoodwinked Medidata Solutions into transferring $4.8m to an "overseas" account this month did not access customer data says the clinical trial IT firm.

The cloud based data management company announced it had been the victim of wire fraud earlier today​, explaining that a request to its finance department had result in the transfer of $4.8m to an unidentified account outside the US on September 16.

"The incident involved a fraudulent request targeting certain mid-level employees in the Company’s finance department, resulting in the transfer of $4.8 million to an overseas account. As a result, the Company expects to record a one-time charge of $4.8 million in its third quarter of 2014​."

Medidata added that the fraud may result in additional costs, but did not provide further details. The US firm also said: "No customer data was involved in this matter and the Company’s systems were not impacted."

The firm has also called in “outside advisors” although it said it believes it has appropriate internal controls that are being reviewed as part of the investigation.

The Company has contacted federal law enforcement authorities and has implemented additional internal procedures to prevent future incidents. While the outcome cannot be assured, the Company is seeking recovery of the funds and intends to file an insurance claim for its loss.”

Collaborators

Medidata’s assurances that customer clinical trial data was not accessed by the fraudsters will be welcome news for contract research organisation (CRO) Icon, which announced it had partnered​ with the IT firm on an electronic patient-reported outcomes (ePROs) project.

The news trial data was not involved will also be welcomed by Big pharma firms like AstraZeneca, Eli Lilly, Johnson & Johnson and GSK, which are all working with Medidata on the development of risk-based monitoring through industry group TransCelerate.

Related news

Show more

Related products

show more

Paper vs ePRO Data Collection Methods

Paper vs ePRO Data Collection Methods

Signant Health | 19-Oct-2021 | Technical / White Paper

Are you curious why more Sponsors choose digital data collection methods over the traditional pen and paper? Read this recent white paper to discover the...

GLP Tissue Cross Reactivity Testing

GLP Tissue Cross Reactivity Testing

Precision for Medicine | 11-Oct-2021 | Product Brochure

Precision for Medicine's unique combination of research services and tissue procurement capabilities form the pillars of our GLP Tissue Cross Reactivity...

Related suppliers

Follow us

Products

View more

Webinars